CBG and CBC kill gastrointestinal cancer cells in preliminary study
A new series of tests in Israel have shown that CBC and CBG both have anti-tumor properties on cancer cells. The tests were carried out by Cannabics Pharmaceuticals at its high-throughput screening (HTS) facilities in Israel. Tests have shown that cannabinoids CBC (Cannabichromene) et CBG (Cannabigerol) both have anti-tumor properties after being tested on human gastrointestinal cancer cells.
CBC and CBG
Funded by the American company Cannabics Pharmaceuticals, a company focused on the development of cannabinoid therapies for the treatment of cancer, Israeli researchers have demonstrated anti-tumor efficacy CBG and CBC against human gastrointestinal cancer cell lines.
CBC is another non-psychoactive cannabinoid and is one of the natural phyto-cannabinoids. It has a host of potential positive therapeutic qualities and can promote antimicrobial, anti-inflammatory, analgesic and neurogenesis activity. It is found in particular in young cannabis plants but only in small amounts.
In these tests, the HTS platform was used to examine the necrotic effects of a variety of cannabinoids on human gastrointestinal cancer cells, in addition to other types of cancer already tested.
CBC and CBG both induced significantly higher rates of necrosis in these cancer cells compared to other cannabinoids.
Dr. Yaakov Waksman, the company's director of cannabidiol research, said: “My working hypothesis is that these results show that there may be a correlation between the value of the topological polar area (TPSA) of a cannabinoid and its ability to induce anti-tumor activity, decreasing the viability rates of cancer cells.
“CBC and CBG, as neutral cannabinoids, both have a TPSA value that allows the cannabinoid molecule to penetrate the membrane of a cancer cell, when their acid form (CBCA and CBGA) - does not not. This could explain the difference in the rate of anti-tumor activity demonstrated ”.
Dr. Eyal Ballan, CTO and co-founder, added: “Gastrointestinal cancers are among the leading and most common causes of cancer death worldwide. We are intrigued by the results we have obtained in the laboratory, and our goal is to consider focusing on this organ system, and further exploring the differential antitumor properties of cannabinoids.
“We believe that these preliminary results confirm our vision, which is to introduce personalization into cancer treatments based on cannabinoids”.